RT Journal Article
SR Electronic
T1 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A859
OP A859
DO 10.1136/jitc-2023-SITC2023.0764
VO 11
IS Suppl 1
A1 Bupathi, Manojkumar
A1 Wang, Judy S
A1 Hu-Lieskovan, Siwen
A1 Piha-Paul, Sarina A
A1 Chmielowski, Bartosz
A1 Garmezy, Benjamin
A1 Najjar, Yana G
A1 Stein, Mark N
A1 Yao, Li
A1 Kanodia, Jitendra
A1 Clynes, Raphael
A1 McGovern, Patricia
A1 Thompson, Benjamin
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A859.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.